Cure Vac Corporate Services GmbH, a wholly owned subsidiary of Cure Vac SE, combines the central functions of the Cure Vac business group. Cure Vac is a global biopharmaceutical company in the field of m RNA technology, with more than 20 years of expertise in researching, developing and optimizing the versatile biological molecule for medical purposes. Our focus is on prophylactic vaccines, innovative cancer immunotherapies, and protein-based therapies. All RNA people are striving to achieve our main joint goal: To bring multiple best-in-class m RNA medicines to market.